Zevra Therapeutics price target raised to $18 from $17 at Citizens JMP

Citizens JMP raised the firm’s price target on Zevra Therapeutics (ZVRA) to $18 from $17 and keeps an Outperform rating on the shares. Zevra reported Q4 revenue that was significantly ahead of consensus estimates, driven by MIPLYFFA U.S. sales, and the MIPLYFFA launch continues to exceed expectations with prescription enrollment forms submitted for 109 patients as of December 31, the analyst tells investors in a research note. The firm expects continued patient additions through 2025, driven by solid awareness of MIPLYFFA in the Niemann-Pick disease type C community.